1
|
Mennen SM, Alhambra C, Allen CL, Barberis M, Berritt S, Brandt TA, Campbell AD, Castañón J, Cherney AH, Christensen M, Damon DB, Eugenio de Diego J, García-Cerrada S, García-Losada P, Haro R, Janey J, Leitch DC, Li L, Liu F, Lobben PC, MacMillan DWC, Magano J, McInturff E, Monfette S, Post RJ, Schultz D, Sitter BJ, Stevens JM, Strambeanu II, Twilton J, Wang K, Zajac MA. The Evolution of High-Throughput Experimentation in Pharmaceutical Development and Perspectives on the Future. Org Process Res Dev 2019. [DOI: 10.1021/acs.oprd.9b00140] [Citation(s) in RCA: 148] [Impact Index Per Article: 29.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Steven M. Mennen
- Drug Substance Technologies, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Carolina Alhambra
- Centro de Investigación Lilly S. A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain
| | - C. Liana Allen
- API Chemistry, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Mario Barberis
- Centro de Investigación Lilly S. A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain
| | - Simon Berritt
- Internal Medicine, Applied Synthesis Technology, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Thomas A. Brandt
- Process Chemistry, Chemical R&D, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Andrew D. Campbell
- Pharmaceutical Technology and Development, AstraZeneca, Silk Road Business Park, Macclesfield, Cheshire SK10 2NA, United Kingdom
| | - Jesús Castañón
- Centro de Investigación Lilly S. A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain
| | - Alan H. Cherney
- Drug Substance Technologies, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Melodie Christensen
- Process Research and Development, Merck & Co., Inc. Rahway, New Jersey 07065, United States
| | - David B. Damon
- Process Chemistry, Chemical R&D, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States
| | - J. Eugenio de Diego
- Centro de Investigación Lilly S. A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain
| | - Susana García-Cerrada
- Centro de Investigación Lilly S. A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain
| | - Pablo García-Losada
- Centro de Investigación Lilly S. A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain
| | - Rubén Haro
- Centro de Investigación Lilly S. A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain
| | - Jacob Janey
- Chemical and Synthetic Development, Bristol-Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States
| | - David C. Leitch
- API Chemistry, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Ling Li
- API Chemistry, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Fangfang Liu
- Pharmaceutical Sciences, Pfizer Global Supply Statistics, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Paul C. Lobben
- Chemical and Synthetic Development, Bristol-Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States
| | - David W. C. MacMillan
- Merck Center for Catalysis at Princeton University, Washington Road, Princeton, New Jersey 08544, United States
| | - Javier Magano
- Process Chemistry, Chemical R&D, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Emma McInturff
- Process Chemistry, Chemical R&D, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Sebastien Monfette
- Process Chemistry, Chemical R&D, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Ronald J. Post
- Engineering Group, Chemical R&D, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Danielle Schultz
- Process Research and Development, Merck & Co., Inc. Rahway, New Jersey 07065, United States
| | - Barbara J. Sitter
- Process Chemistry, Chemical R&D, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jason M. Stevens
- Chemical and Synthetic Development, Bristol-Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States
| | - Iulia I. Strambeanu
- API Chemistry, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Jack Twilton
- Merck Center for Catalysis at Princeton University, Washington Road, Princeton, New Jersey 08544, United States
| | - Ke Wang
- Pharmaceutical Sciences, Pfizer Global Supply Statistics, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Matthew A. Zajac
- API Chemistry, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| |
Collapse
|
3
|
Abstract
We demonstrate a high-throughput chemoprinting platform that confirms the consistency in the higher-order structure of protein biologics and is sensitive enough to detect single-point mutations. This method addresses the quality and consistency of the tertiary and quaternary structure of biologic drug products, which is arguably the most important, yet rarely examined, parameter. The method described uses specific small-molecule ligands as molecular probes to assess protein structure. Each library of probe molecules provides a "fingerprint" when taken holistically. After proof-of-concept experiments involving enzymes and antibodies, we were able to detect minor conformational perturbations between four 48 kDa protein mutants that only differ by one amino acid residue.
Collapse
Affiliation(s)
- Caterina Musetti
- Platform Technology and Science, GlaxoSmithKline , 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Mark F Bean
- Platform Technology and Science, GlaxoSmithKline , 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Geoffrey T Quinque
- Platform Technology and Science, GlaxoSmithKline , 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Christopher Kwiatkowski
- Platform Technology and Science, GlaxoSmithKline , 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Lawrence M Szewczuk
- Platform Technology and Science, GlaxoSmithKline , 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - John Baldoni
- Platform Technology and Science, GlaxoSmithKline , 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Matthew A Zajac
- Platform Technology and Science, GlaxoSmithKline , 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| |
Collapse
|
7
|
Dineen TA, Zajac MA, Myers AG. Efficient Transamidation of Primary Carboxamides by in Situ Activation with N,N-Dialkylformamide Dimethyl Acetals. J Am Chem Soc 2006; 128:16406-9. [PMID: 17165798 DOI: 10.1021/ja066728i] [Citation(s) in RCA: 128] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Two protocols for the transamidation of primary amides with primary and secondary amines, forming secondary and tertiary amides, respectively, are described. Both processes employ N,N-dialkylformamide dimethyl acetals for primary amide activation, producing N'-acyl-N,N-dialkylformamidines as intermediates, as widely documented in the literature. Although the latter intermediates react irreversibly with amines by amidinyl transfer, we show that in the presence of certain Lewis acid additives efficient acyl transfer occurs, providing new and useful methods for amide exchange. In one protocol for transamidation, the N'-acyl-N,N-dialkylformamidine intermediates are purified by flash-column chromatography and the purified intermediates are then treated with an amine (typically, 2.5 equiv) in the presence of scandium triflate (10 mol %) in ether to form in high yields the products of transamidation. In a second procedure, N'-acyl-N,N-dialkylformamidines are generated in situ and, without isolation, are subjected to transamidation in the presence of zirconium chloride (0.5 equiv) and an amine (typically 2 equiv). A variety of different primary amides and amines are found to undergo efficient transamidation using the methods described.
Collapse
Affiliation(s)
- Thomas A Dineen
- Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, USA
| | | | | |
Collapse
|